The DOI matches its Crossref record; 49 of the 51 references it cites were found in a registry or an index; 5 of the 8 sources its claims cite were checked for support.
A quantitative modeling framework to understand the physiology of the hypothalamic-pituitary-adrenal axis and interaction with cortisol replacement therapy
Open accessAbstract
Congenital adrenal hyperplasia (CAH) is characterized by impaired adrenal cortisol production. Hydrocortisone (synthetic cortisol) is the drug-of-choice for cortisol replacement therapy, aiming to mimic physiological cortisol circadian rhythm. The hypothalamic-pituitary-adrenal (HPA) axis controls cortisol production through the pituitary adrenocorticotropic hormone (ACTH) and feedback mechanisms. The aim of this study was to quantify key mechanisms involved in the HPA axis activity regulation and their interaction with hydrocortisone therapy. Data from 30 healthy volunteers was leveraged: Endogenous ACTH and cortisol concentrations without any intervention as well as cortisol concentrations measured after dexamethasone suppression and single dose administration of (i) 0.5–10 mg hydrocortisone as granules, (ii) 20 mg hydrocortisone as granules and intravenous bolus. A stepwise model development workflow was used: A newly developed model for endogenous ACTH and cortisol was merged with a refined hydrocortisone pharmacokinetic model. The joint model was used to simulate ACTH and cortisol trajectories in CAH patients with varying degrees of enzyme deficiency, with or without hydrocortisone administration, and healthy individuals. Time-dependent ACTH-driven endogenous cortisol production and cortisol-mediated feedback inhibition of ACTH secretion processes were quantified and implemented in the model. Comparison of simulated ACTH and cortisol trajectories between CAH patients and healthy individuals showed the importance of administering hydrocortisone before morning ACTH secretion peak time to suppress ACTH overproduction observed in untreated CAH patients. The developed framework allowed to gain insights on the physiological mechanisms of the HPA axis regulation, its perturbations in CAH and interaction with hydrocortisone administration, paving the way towards cortisol replacement therapy optimization. Graphical Abstract
Overview
CoChat Summary
## TL;DR
The paper develops a quantitative nonlinear mixed-effects model of the HPA axis that links ACTH, cortisol production, and hydrocortisone pharmacokinetics in healthy adults. Using simulations, it shows that in severe CAH, giving immediate-release hydrocortisone before the morning ACTH peak (05:00 rather than 07:00) better suppresses ACTH overproduction.
## Key findings
- The final joint model quantified ACTH-driven cortisol production with an estimated maximal cortisol production rate of 5440 nmol/h and EC50 = 6.63 pmol/L; a typical 70 kg healthy individual remained below 50% of maximal cortisol production, about 2200 nmol/h.
- Cortisol feedback inhibition on ACTH secretion was modeled with an estimated IC50 = 4.60 nmol/L unbound cortisol (about 160 nmol/L total cortisol) and Imax fixed to 99.9%, implying ACTH pulsatile secretion was almost fully suppressed during daytime.
- In simulations, mild CAH produced cortisol trajectories similar to healthy individuals, but ACTH morning peak concentrations were about 10-fold higher; severe CAH produced negligible cortisol and about 100-fold higher ACTH morning peaks than healthy individuals.
- For severe CAH, 10 mg immediate-release hydrocortisone at 05:00 reduced ACTH overproduction more than the same dose at 07:00; dosing at 07:00 looked similar to untreated severe CAH because it was after the healthy ACTH peak time.
## Methods
- Two cross-over phase I trials in healthy male adults were analyzed: the first trial had N = 16, the second N = 14, with one participant excluded from the second trial for insufficient ACTH suppression; the total analyzed population was n = 29.
- The modeling workflow had three steps: refine a hydrocortisone PK model, build an endogenous ACTH-cortisol model using surge functions plus baseline secretion and cortisol feedback inhibition, then merge them into a joint model with simultaneous re-estimation.
- Model selection used GOF plots, dOFV/AIC, visual predictive checks (n = 1000), and sampling importance resampling; simulations were run for n = 1000 virtual trajectories in 70 kg healthy and CAH individuals.
## Limitations
- The paper states that ultradian rhythm was not modeled because it would require denser-than-hourly sampling; this limits the framework to circadian behavior.
- It states that the endogenous ACTH-cortisol submodel was developed from only N = 13 healthy participants and that some plausible variability, such as IIV on ACTH secretion peak time, could not be estimated. The text also notes several modeling assumptions: cortisol production was assumed to depend only on ACTH, and in hydrocortisone simulations severe CAH was assumed to produce no cortisol; these are acknowledged by the authors as simplifying assumptions.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures


![Fig. 3 Goodness of fit plots (observations versus population predictions for different hydrocortisone absorption models: Left panels for the original saturable absorption model [20], middle panels for developed ABS1 (“split-dose”) model, right panels for developed ABS2 (“estimating number of transit compartments”) model. Top panels for 20 mg oral hydrocortisone administration and bottom panels for 20 mg intravenous (i.v.) bolus hydrocortisone administration](https://figures.cochat.ai/paper-figures/da78daf81ca24a1e813a78e51b86684c/a-quantitative-modeling-framework-to-understand-the-physiology-of-the-figure-3.jpg)




Verification
Claims the paper makes
4 Valid · 0 Not valid · 1 Not checked · 36 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“This process is comparably accounted for in our framework by the presence of a peripheral compartment for cortisol.”
§ A quantitative modeling framework to understand the physiology of the hypothalamic-pituitary-adrenal axis and interaction with cortisol replacement therapy > Discussion
What the sources say
- Supportedcites [42] Dorin RI, Urban FK, Perogamvros I, Qualls CR (2022) Four-compartment diffusion model of Cortisol Disposition: comparison with 3 alternative models in current clinical use. J Endocr Soc 7:1–13. https://doi.org/10.1210/JENDSO/BVAC173 source
The Abstract describes Dorin et al.’s model as including an extravascular distribution volume for cortisol. The Discussion likewise says the model accounts for cortisol distribution in the extravascular compartment. The comparison to a peripheral compartment is the citing authors’ description of their own framework, not a finding attributed to Dorin et al. (LLM, conf=0.91)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Additionally, the reported elimination rate constant for unbound cortisol (53.4 h− 1) is well in accordance with our estimated value (49.3 h− 1).”
§ A quantitative modeling framework to understand the physiology of the hypothalamic-pituitary-adrenal axis and interaction with cortisol replacement therapy > Discussion
What the sources say
- Supportedcites [42] Dorin RI, Urban FK, Perogamvros I, Qualls CR (2022) Four-compartment diffusion model of Cortisol Disposition: comparison with 3 alternative models in current clinical use. J Endocr Soc 7:1–13. https://doi.org/10.1210/JENDSO/BVAC173 source
Table 2 reports a Model 4 elimination rate constant of α₄ = 0.89 ± 0.13 min⁻¹ for healthy volunteers; 0.89 × 60 = 53.4 h⁻¹. The paper’s limitations discussion identifies α₄ as the term representing elimination of free cortisol. The citing authors’ 49.3 h⁻¹ estimate is their own comparison, not a value attributed to this source. (LLM, conf=0.93)
boosted- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The increased absorption delay at higher doses can be explained by the low aqueous solubility of hydrocortisone (0.35–0.40 mg/mL) [29].”
§ A quantitative modeling framework to understand the physiology of the hypothalamic-pituitary-adrenal axis and interaction with cortisol replacement therapy > Results > Step 3: joint model and parameters re-estimation
What the sources say
- Partly supportedcites [29] Wollmer E, Karkossa F, Freerks L et al (2020) A Biopredictive in Vitro Approach for assessing compatibility of a Novel Pediatric Hydrocortisone Drug Product within Common Pediatric Dosing vehicles. Pharm Res 37. https://doi.org/10.1007/S11095-020-02912-X sourceExperimental — accuracy not yet measured
The Introduction (page unavailable) reports aqueous solubility of 0.35–0.40 mg/mL, supporting the quoted value. It does not attribute increased absorption delay at higher doses to that solubility; instead, the Introduction and Results and Discussion say solubility should not be an issue across the pediatric doses studied. (LLM, conf=0.88)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Similarly, when hydrocortisone was administered too late (i.e. after the ACTH secretion peak time of healthy individuals e.g., at 07:00), ACTH concentration trajectories were similar to the ones in untreated CAH patients (Fig. 7, bottom).”
§ A quantitative modeling framework to understand the physiology of the hypothalamic-pituitary-adrenal axis and interaction with cortisol replacement therapy > Results > Simulations: interaction with hydrocortisone therapy
plainn = 1,000- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The ACTH concentration – cortisol production rate relationship was best characterized by a sigmoidal Emax model compared to linear, log-linear and Emax effect models (dOFV=-256, -209, -260), respectively.”
§ A quantitative modeling framework to understand the physiology of the hypothalamic-pituitary-adrenal axis and interaction with cortisol replacement therapy > Results > Step 2: endogenous ACTH and cortisol model
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
10 more claims
Create a free account to see all 41 claims and every source verdict.
- It may state two separate claims as one. 26
- The quote only partly states this claim. 1
Citations
Cites
Hypothalamic-pituitary-adrenal axis, neuroendocrine factors and stress
Tsigos, C., & Chrousos, G. P. (2002) · Journal of Psychosomatic Research · doi:10.1016/s0022-3999(02)00429-4 · Cited by 2,822 · cited 1×
“This assumption overlooked the known contributions of other glucocorticoids to the feedback mechanism [ 44, 45].”
Regulation of the Hypothalamic‐Pituitary‐Adrenocortical Stress Response
Herman, J. P., McKlveen, J. M., Ghosal, S., Kopp, B., Wulsin, A., Makinson, R., Scheimann, J., & Myers, B. (2016) · Comprehensive Physiology · doi:10.1002/cphy.c150015 · Cited by 1,819 · cited 1×
“This assumption overlooked the known contributions of other glucocorticoids to the feedback mechanism [ 44, 45].”
Speiser, P. W., Azziz, R., Baskin, L. S., Ghizzoni, L., Hensle, T. W., Merke, D. P., Meyer-Bahlburg, H. F. L., Miller, W. L., Montori, V. M., Oberfield, S. E., et al. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2631 · Cited by 1,468 · cited 1×
“Congenital adrenal hyperplasia patients require lifelong cortisol replacement therapy, with hydrocortisone (synthetic cortisol) being the preferred drug for cortisol replacement [ 3, 12].”
Global Disorders of Sex Development Update since 2006: Perceptions, Approach and Care
Lee, P. A., Nordenström, A., Houk, C. P., Ahmed, S. F., Auchus, R., Baratz, A., Baratz Dalke, K., Liao, L.-M., Lin-Su, K., Looijenga 3rd, L. H. J., et al. (2016) · Hormone Research in Paediatrics · doi:10.1159/000442975 · Cited by 1,273
Speiser, P. W., Arlt, W., Auchus, R. J., Baskin, L. S., Conway, G. S., Merke, D. P., Meyer-Bahlburg, H. F. L., Miller, W. L., Murad, M. H., Oberfield, S. E., et al. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-01865 · Cited by 1,234
Quantification of Lean Bodyweight
Janmahasatian, S., Duffull, S. B., Ash, S., Ward, L. C., Byrne, N. M., & Green, B. (2005) · Clinical Pharmacokinetics · doi:10.2165/00003088-200544100-00004 · Cited by 900
Seckl, J. R., & Walker, B. R. (2001) · Endocrinology · doi:10.1210/endo.142.4.8114 · Cited by 714
Congenital adrenal hyperplasia
El-Maouche, D., Arlt, W., & Merke, D. P. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31431-9 · Cited by 669
Congenital adrenal hyperplasia.
Merke, D. P., & Bornstein, S. R. (2005) · The Lancet · doi:10.1016/s0140-6736(05)66736-0 · Cited by 628
Congenital Adrenal Hyperplasia—Current Insights in Pathophysiology, Diagnostics, and Management
Claahsen - van der Grinten, H. L., Speiser, P. W., Ahmed, S. F., Arlt, W., Auchus, R. J., Falhammar, H., Flück, C. E., Guasti, L., Huebner, A., Kortmann, B. B. M., et al. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnab016 · Cited by 556 · cited 5×
“Congenital adrenal hyperplasia patients require lifelong cortisol replacement therapy, with hydrocortisone (synthetic cortisol) being the preferred drug for cortisol replacement [ 3, 12].”
Influential
Cited by
Research Progress on the Pathogenesis of Post-Stroke Depression
Chen, J., Li, W., Por, J., Liu, H., Shen, Y., & Cai, L. (2025) · ACS Omega · doi:10.1021/acsomega.5c05338 · Cited by 8
Bindellini, D., Michelet, R., Mirasbekov, Y., Lao, Q., Sukin, C., Huisinga, W., Merke, D. P., & Kloft, C. (2025) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.70086 · Cited by 2
Self-citationAssociation between blood cortisol levels and numerical rating scale in prehospital pain assessment
López‐Izquierdo, R., Ingelmo-Astorga, E. A., Vegas, C. D. P., Villar, S. G., López, L. A. D., Obregón, S. A., Iglesias, R. C., García, A. S., & Rodríguez, F. M. (2025) · Communications Medicine · doi:10.1038/s43856-025-01020-4 · Cited by 2
“Research has shown that the hypothalamic ‒ pituitary ‒ adrenal axis is triggered in painful conditions, resulting in increased bioavailability of cortisol 10 .”
The evolution of new approaches to the treatment of congenital adrenal hyperplasia
Merke, D. P., & Auchus, R. J. (2026) · Endocrine Reviews · doi:10.1210/endrev/bnag033
Metadata
- Authors
- Bindellini, D., Michelet, R., Aulin, L. B. S., Melin, J., Neumann, U., Blankenstein, O., Huisinga, W., Whitaker, M. J., Ross, R., & Kloft, C.
- Affiliations
- Freie Universität Berlin (DE)
- Charité – Universitätsmedizin Berlin (DE)
- University of Potsdam (DE)
- University of Sheffield (GB)
- Corresponding author
- Michelet, Robin
- ORCID
- Venue
- Journal of Pharmacokinetics and Pharmacodynamics
- Published
- 2024-07-08
- Volume
- 51
- Issue
- 6
- Pages
- 809-824
- ISSN
- 1567-567X (ISSN-L)
- 1573-8744
- PMC
- PMC11579075
- OpenAlex
- W4400413471
- Cited by
- 4
- References
- 51
- Citations by year
- 2026: 1 · 2025: 3
- FWCI
- 1.31
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Journal of Pharmacokinetics and Pharmacodynamics (publishedVersion, cc-by)
- PubMed Central (publishedVersion, other-oa)
- PubMed (publishedVersion)
- White Rose Research Online (University of Leeds, The University of Sheffield, University of York) (acceptedVersion, other-oa)
- Refubium (Universitätsbibliothek der Freien Universität Berlin) (submittedVersion, cc-by)
- PUBLISSO (German National Library of Medicine) (submittedVersion, cc-by)
- Universitätsbibliothek der FU Berlin Hochschulschriftenstelle u. Dokumentenserver (cc-by)
- Funders
- Freie Universität Berlin
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Life Sciences › Neuroscience › Behavioral Neuroscience › Stress Responses and Cortisol
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Sexual Differentiation and Disorders
- Keywords
- congenital adrenal hyperplasia, hypothalamic-pituitary-adrenal axis, cortisol, cortisol replacement therapy, ACTH secretion, dexamethasone suppression test, diurnal cortisol rhythm, enzyme deficiency
- MeSH terms
- Adrenal Hyperplasia, Congenital, Adrenocorticotropic Hormone, Adult, Circadian Rhythm, Dexamethasone, Female, Humans, Hydrocortisone, Hypothalamo-Hypophyseal System, Male, Middle Aged, Models, Biological, Pituitary-Adrenal System, Hormone Replacement Therapy, Young Adult, Healthy Volunteers
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-09, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-09 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A quantitative modeling framework to understand the physiology of the hypothalamic-pituitary-adrenal axis and interaction with cortisol replacement therapy. https://app.cochat.ai/papers/10.1007/s10928-024-09934-7
- The paper
- Bindellini, D., Michelet, R., Aulin, L. B. S., Melin, J., Neumann, U., Blankenstein, O., Huisinga, W., Whitaker, M. J., Ross, R., & Kloft, C. (2024). A quantitative modeling framework to understand the physiology of the hypothalamic-pituitary-adrenal axis and interaction with cortisol replacement therapy. Journal of Pharmacokinetics and Pharmacodynamics. https://doi.org/10.1007/s10928-024-09934-7
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.